...
机译:口服合成类视黄醇他米巴罗汀治疗后晚期急性早幼粒细胞白血病的分子缓解
Department of Biopathology, University of Rome ‘Tor Vergata’;
Department of Biopathology, University of Rome ‘Tor Vergata’|Laboratory of Neuro-Oncohaematology, Fondazione Santa Lucia, Rome, Italy;
Department of Biopathology, University of Rome ‘Tor Vergata’;
Department of Biopathology, University of Rome ‘Tor Vergata’;
Department of Biopathology, University of Rome ‘Tor Vergata’;
Drug Development, CytRx Corporation, Los Angeles, CA, USA. E-mail: francesco.lo.coco@uniroma2.it;
Department of Biopathology, University of Rome ‘Tor Vergata’;
Department of Biopathology, University of Rome ‘Tor Vergata’;
Department of Biopathology, University of Rome ‘Tor Vergata’;
Department of Biopathology, University of Rome ‘Tor Vergata’|Laboratory of Neuro-Oncohaematology, Fondazione Santa Lucia, Rome, Italy;
机译:口服合成类视黄醇他米巴罗汀治疗后晚期急性早幼粒细胞白血病的分子缓解。
机译:具有新的合成类含量的坦替烯(AM-80)的临床经验,用于复发或难治性急性早幼粒细胞白血病
机译:新型合成类视黄醇他米巴罗汀(Am-80)在复发或难治性急性早幼粒细胞白血病中的临床经验
机译:急性高幼苗细胞白血病的分子遗传学:癌症“转录治疗”的理由
机译:合成类视黄醇N-(4-羟苯基)视黄酰胺的分子作用机理。
机译:全反式维甲酸和三氧化二砷治疗后急性早幼粒细胞白血病复发的替米巴罗汀
机译:口服合成类视黄醇他米巴罗汀治疗后晚期急性早幼粒细胞白血病的分子缓解
机译:荷兰儿童急性淋巴细胞白血病。根据方案aLL II(荷兰儿童白血病研究组)和停止治疗后的免疫学研究的治疗结果